{
    "nctId": "NCT00198237",
    "briefTitle": "Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer",
    "officialTitle": "Genomic and Proteomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "The primary objective of this study is to determine the efficacy & toxicity of combined docetaxel & capecitabine as primary chemotherapy for subjects with stage II-III breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the breast w/ Stage II-III disease w/ a primary tumor \\>/=2cm or clinically palpable axillary lymph nodes.\n* Pre-treatment core or incisional bx w/ adequate tissue for histology \\& genomic/proteomic analysis.\n* Primary tumor must be bi-dimensionally measurable by physical exam or dx breast imaging. Measurements must be obtained w/in 3 wks prior to study entry.\n* Adequate organ fxn:AGC\\>1500; Hb\\>/=9.0;plts\\>/=100K; Crt\\</=2.0;Cacl Crt Clr\\>/=50; total bili\\</=ULN; LFTs\\<2.0 ULN\n* ECOG performance status 0-1\n* Neg. pregnancy test\n\nExclusion Criteria:\n\n* Pts may not have had definitive primary surgery.\n* Metastatic breast cancer\n* Any prior chemo or hormonal therapy for breast cancer\n* Prior history of malignancy w/in the previous 5 yrs.\n* No active unresolved infection\n* No major surgery w/in 2wks of start of study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}